Received: 6 September 2021
Accepted: 5 October 2021
First Online: 15 November 2021
: This study has been approved by the appropriate ethics committee (EA4/053/17) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Not applicable.
: JZ, US, ES, FK, CP, WS declare that they have no competing interests. KH received financial reimbursement for consulting and advisory board activities and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc. and Swedish Orphan Biovitrum Inc.. KH further received research funding by the foundation Charité (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals, all outside the submitted work.